Tyk2 Targeting in Immune-Mediated Inflammatory Diseases

Lluís Rusiñol, Lluís Puig Sanz

Producción científica: Contribución a una revistaArtículo de revisiónInvestigaciónrevisión exhaustiva

18 Citas (Scopus)

Resumen

The Janus kinase (Jak)/signal transducer and activating protein (STAT) pathways mediate the intracellular signaling of cytokines in a wide spectrum of cellular processes. They participate in physiologic and inflammatory cascades and have become a major focus of research, yielding novel therapies for immune-mediated inflammatory diseases (IMID). Genetic linkage has related dysfunction of Tyrosine kinase 2 (Tyk2)-the first member of the Jak family that was described-to protection from psoriasis. Furthermore, Tyk2 dysfunction has been related to IMID prevention, without increasing the risk of serious infections; thus, Tyk2 inhibition has been established as a promising therapeutic target, with multiple Tyk2 inhibitors under development. Most of them are orthosteric inhibitors, impeding adenosine triphosphate (ATP) binding to the JH1 catalytic domain-which is highly conserved across tyrosine kinases-and are not completely selective. Deucravacitinib is an allosteric inhibitor that binds to the pseudokinase JH2 (regulatory) domain of Tyk2; this unique mechanism determines greater selectivity and a reduced risk of adverse events. In September 2022, deucravacitinib became the first Tyk2 inhibitor approved for the treatment of moderate-to-severe psoriasis. A bright future can be expected for Tyk2 inhibitors, with newer drugs and more indications to come.
Idioma originalInglés
Número de artículo3391
PublicaciónInternational Journal of Molecular Sciences
Volumen24
N.º4
DOI
EstadoPublicada - feb 2023

Huella

Profundice en los temas de investigación de 'Tyk2 Targeting in Immune-Mediated Inflammatory Diseases'. En conjunto forman una huella única.

Citar esto